IBD patients have chronic inflammation which is an underlying risk factor for colon cancer, and mouse models demonstrate that tumor necrosis factor α (TNF-α), a target of IBD treatments, plays a critical role in development of inflammation-induced colon cancer [48–50]. This evidence concerns the gene TNF and inflammatory bowel disease.